Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
doi: 10.1038/s12276-018-0084-3 29 KangZ.ZengJ.ZhangT.LinS.GaoJ.JiangC.et al
1 Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as non-alcoholic fatty liver disease (NAFLD), has become the most prevalent chronic liver condition worldwide, affecting approximately one-third to nearly 40% of the adult population globally, with projections indicating an increase to over 55% by 2040 ( (THR-) agonist, received approval from the FDA in 2024 for the treatment of adult patients with F2-F3 MASH ( Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained considerable attention in recent years as promising therapeutic agents for MASLD, particularly owing to their well-established efficacy in treating type 2 diabetes mellitus (T2DM) and obesity, conditions closely implicated to MASLD pathogenesis ( This review aims to systematically summarize the mechanistic insights and clinical advances of GLP-1with dual or triple receptor agonists in MASLD treatment, thereby promoting a more profound comprehension and facilitating their application in clinical practice (Figure 1)
Beyond their metabolic effects, emerging evidence suggests that GLP-1 agonists may influence central pathways involved in appetite regulation, reward processing, inflammation, and mood
however, those with alcohol usage disorders randomized to receive exenatide once weekly over 26 weeks showed no reduction in heavy drinking
